• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    President & CEO Eglinton Manner Carrie covered exercise/tax liability with 193,249 shares and was granted 335,710 shares, increasing direct ownership by 8% to 1,830,827 units (SEC Form 4)

    6/5/25 7:16:13 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care
    Get the next $OSUR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    EGLINTON MANNER CARRIE

    (Last) (First) (Middle)
    C/O ORASURE TECHNOLOGIES, INC.
    220 EAST FIRST STREET

    (Street)
    BETHLEHEM PA 18015

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ORASURE TECHNOLOGIES INC [ OSUR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President & CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    06/04/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/04/2025 A 335,710(1) A $0 2,024,076 D
    Common Stock 06/04/2025 F 146,000(2) D $2.9 1,878,076 D
    Common Stock 06/04/2025 F 47,249(3) D $2.9 1,830,827 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares delivered in settlement of vested performance units that did not constitute a derivative security.
    2. Withholding of shares to pay tax liability associated with the vesting of performance units.
    3. Withholding of shares to pay the tax liability associated with vesting of restricted shares.
    /s/ Michele Anthony, Attorney-In-Fact 06/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OSUR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSUR

    DatePrice TargetRatingAnalyst
    1/3/2023$5.00In-line
    Evercore ISI
    2/24/2022$15.00 → $12.00Buy
    Citigroup
    9/22/2021Outperform → Market Perform
    Raymond James
    8/4/2021$11.00 → $12.50Outperform
    Raymond James
    6/28/2021$12.00 → $11.00Outperform
    Raymond James
    More analyst ratings

    $OSUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gagliano Nancy J bought $39,270 worth of shares (12,750 units at $3.08), increasing direct ownership by 16% to 91,524 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      3/3/25 9:08:13 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • President & CEO Eglinton Manner Carrie bought $100,027 worth of shares (28,670 units at $3.49), increasing direct ownership by 2% to 1,288,334 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      3/3/25 9:07:25 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • President & CEO Eglinton Manner Carrie bought $247,378 worth of shares (78,625 units at $3.15), increasing direct ownership by 7% to 1,259,664 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      2/27/25 9:14:53 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Eglinton Manner Carrie covered exercise/tax liability with 193,249 shares and was granted 335,710 shares, increasing direct ownership by 8% to 1,830,827 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      6/5/25 7:16:13 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Director Kenny John P. was granted 71,017 shares, increasing direct ownership by 102% to 140,547 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      5/15/25 4:46:39 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Director Gagliano Nancy J covered exercise/tax liability with 4,387 shares and was granted 71,017 shares, increasing direct ownership by 73% to 158,154 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      5/15/25 4:46:26 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    SEC Filings

    See more
    • SEC Form EFFECT filed by OraSure Technologies Inc.

      EFFECT - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

      5/30/25 12:15:20 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by OraSure Technologies Inc.

      S-8 - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

      5/20/25 5:26:03 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • SEC Form S-3 filed by OraSure Technologies Inc.

      S-3 - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

      5/20/25 5:13:17 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing

      IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Targeted Genomics LLC, developer of GlutenID, the first and only U.S. Food and Drug Administration (FDA) cleared direct-to-consumer (DTC) test for celiac disease genetics, today announced a commercial collaboration with OraSure Technologies, Inc. (NASDAQ:OSUR) manufacturer of ORAcollect®·Dx, the only FDA cleared saliva collection device for general over-the-counter (OTC) use. The collaboration expands consumer access to at-home celiac genetic testing.  Celiac disease, the most common intestinal autoimmune disease worldwide, is triggered by dietary gluten in people who carry the DQ2 and/or DQ8 celiac risk genes. Individuals who test negative

      5/14/25 8:00:00 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Announces First Quarter 2025 Financial Results

      BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. "Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some segments," said OraSure President and CEO Carrie Eglinton Manner. "We are making good progress in advancing our innovation roadmap, including multiple new prod

      5/7/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th

      BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately one year. For participants interested

      4/23/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Leadership Updates

    Live Leadership Updates

    See more
    • KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

      6/7/24 6:09:00 PM ET
      $ADTN
      $ALTR
      $ATNI
      $BMRN
      Telecommunications Equipment
      Utilities
      Computer Software: Prepackaged Software
      Technology
    • NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

      Former Head of OraSure Technologies Joins at Key Stage Leading up to Company's Product Launch NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321747977/en/NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire) Dr. Tang is a longtime veteran of the medical diagnostic industry. He led OraSure Technologies, Inc. (NASDA

      3/21/24 8:31:00 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary

      BETHLEHEM, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that after almost 21 years of service to the Company, Jack E. Jerrett is retiring as the Company's Senior Vice President, General Counsel, Chief Compliance Officer and Secretary, effective as of December 31, 2021. Agnieszka M. Gallagher, who most recently served as the Chief Ethics and Compliance Officer at Alnylam Pharmaceuticals has been hired by the Company to fill Jack's roles as the new General Counsel, Chief Compliance Officer and Secretary. "Jack has been a stalwart and extremely

      11/9/21 7:05:00 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Financials

    Live finance-specific insights

    See more

    $OSUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • OraSure Announces First Quarter 2025 Financial Results

      BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. "Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some segments," said OraSure President and CEO Carrie Eglinton Manner. "We are making good progress in advancing our innovation roadmap, including multiple new prod

      5/7/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th

      BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately one year. For participants interested

      4/23/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Reports Fourth Quarter 2024 Financial Results

      BETHLEHEM, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2024. "Our Q4 revenue was consistent with our expectations, including 10% growth in our core revenue. We continue to see signs of gradual recovery in our key end markets, and we are diversifying our business by expanding our product portfolio and adding new customers, offset by elevated uncertainty for some of our existing customers related to government funding sources," said OraSure President and CEO Carrie Eglinton Manner. "We made tre

      2/25/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

      SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

      11/12/24 4:46:06 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

      SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

      11/4/24 1:18:55 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by OraSure Technologies Inc.

      SC 13G - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

      10/4/24 1:30:36 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI resumed coverage on OraSure with a new price target

      Evercore ISI resumed coverage of OraSure with a rating of In-line and set a new price target of $5.00

      1/3/23 8:07:55 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Citigroup reiterated coverage on OraSure Technologies with a new price target

      Citigroup reiterated coverage of OraSure Technologies with a rating of Buy and set a new price target of $12.00 from $15.00 previously

      2/24/22 8:34:18 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Technologies downgraded by Raymond James

      Raymond James downgraded OraSure Technologies from Outperform to Market Perform

      9/22/21 5:02:16 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care